Form 4: Apellis Officer Sells Shares for Tax Withholding

Apellis Pharmaceuticals' Chief Business & Strategy Officer, Mark DeLong, sold 368 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, Inc. (APLS), reported a transaction.
• The transaction involved the sale of 368 shares of Apellis Pharmaceuticals Common Stock.
• The shares were sold on February 11, 2026, at a price of $22.1537 per share.
• The purpose of the sale was to cover tax withholding obligations on Restricted Stock Units (RSUs) that were released on February 10, 2026.
• Following this transaction, Mark DeLong beneficially owns 114,591 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was for tax purposes and not a discretionary divestment, which is a common occurrence for executives receiving equity compensation.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that routine tax-related sales by corporate insiders, such as the one reported by Mark DeLong, are a common occurrence when Restricted Stock Units (RSUs) vest. These transactions are typically pre-arranged under Rule 10b5-1 plans and are generally not indicative of a change in the insider's sentiment regarding the company's future prospects or a broader industry trend.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes, not signaling a change in company fundamentals or insider confidence.

Key Dates

Recommendation

The transaction is a routine sale of shares to cover tax obligations upon the vesting of Restricted Stock Units, which is a common practice and does not reflect a change in the insider's view of the company's fundamentals or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Apellis Pharmaceuticals, APLS, Form 4, insider transaction, stock sale, tax withholding, restricted stock units, Mark DeLong